SLC5A2 and myocardial infarction: In prospective and retrospective clinical studies, the early initiation of an SGLT2-i after myocardial infarction (MI) was associated with a reduced risk of adverse cardiovascular events, lower mortality and improved echocardiographic parameters [4, 5].